London-based Hashimoto startup Hashiona has announced the close of a €450K pre-seed round. The company was founded in early 2020 and initially launched in January 2021. Hashiona has since acquired hundreds of beta-users, who use the app to track symptoms and connect with providers via telehealth. Draper University, KAYA, DFRI, Calm/Storm, as well as angel investors participated in the round.
Hashimoto is an autoimmune disease that damages the thyroid gland and the most common cause of hypothyroidism. If left untreated hypothyroidism can cause problems getting pregnant and during pregnancy. Symptoms also include enlargement of fatigue, weight gain, hair or skin changes, depression, and joint pain. Women are disproportionally affected and are about 7 times more likely to have the disease than men.
Blood tests measuring thyroid hormone levels are used to diagnose Hashimoto. There is no cure for Hashimoto, but medication that can help regulate hormone levels and restore a patient’s metabolism.
The startup plans to use the new funds to develop a multi-week step-by-step treatment program that can be personalized and tailered to each patient through a combination of medical records and user’s lifestyle.
